Oxidative Damage, CYP1B1 and Breast Cancer

2002 ◽  
Author(s):  
Regine Goth-Goldstein
Keyword(s):  
Breast Cancer ◽  
Oxidative Damage

scholarly journals Chronic-Leptin Attenuates Cisplatin Cytotoxicity in MCF-7 Breast Cancer Cell Line

2015 ◽  
Vol 36 (1) ◽  
pp. 221-232 ◽  
Author(s):  
Mercedes Nadal-Serrano ◽  
Jorge Sastre-Serra ◽  
Adamo Valle ◽  
Pilar Roca ◽  
Jordi Oliver
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Oxidative Damage ◽  
Large Scale ◽  
Tumor Development ◽  
Cancer Cell Line ◽  
Tumor Formation ◽  
Antioxidant Systems ◽  
Ros Production ◽  
Mcf 7

Background/Aims: Large-scale epidemiological studies support a correlation between obesity and breast cancer in postmenopausal women. Circulating leptin levels are increased in obese and it has been suggested to play a significant role in mammary tumor formation and progression. Moreover, regulation of oxidative stress is another important factor in both tumor development and responses to anticancer therapies. The aim of this study was to examine the relationship between oxidative stress and chronic leptin exposure. Methods: We treated MCF-7 breast cancer cells with 100 ng/mL leptin for 10 days and analyzed cell growth, ROS production and oxidative damage, as well as, some of the main antioxidant systems. Furthermore, since the hyperleptinemia has been associated with a worse pathology prognosis, we decided to test the influence of leptin in response to cisplatin anticancer treatment. Results: Leptin signalling increased cell proliferation but reduced ROS production, as well as, oxidative damage. We observed an upregulation of SIRT1 after leptin exposure, a key regulator of stress response and metabolism. Additionally, leptin counteracted cisplatin-induced cytotoxicity in tumor cells, showing a decrease in cell death. Conclusion: Chronic leptin could contribute to the effective regulation of endogenous and treatment-induced oxidative stress, and it contributes to explain in part its proliferative effects.

scholarly journals Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1501 ◽  
Author(s):  
Sawczuk ◽  
Maciejczyk ◽  
Sawczuk-Siemieniuk ◽  
Posmyk ◽  
Zalewska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Salivary Gland ◽  
Oxidative Damage ◽  
Cancer Progression ◽  
Brca1 Mutation ◽  
Total Antioxidant Status ◽  
Redox Balance ◽  
Breast Cancer Patients ◽  
Total Antioxidant ◽  
Oxidative Damage To Proteins

: Oxidative stress plays a key role in breast cancer progression. However, little is still known about the relationship between the BRCA1 mutation, the incidence of breast cancer and oral homeostasis. This is the first study to evaluate the secretory function of salivary glands, biomarkers of redox balance, and oxidative damage to proteins and lipids in the saliva of subjects with the BRCA1 mutation. Ninety eight women were enrolled in the study and allocated to four groups based on molecular DNA testing: generally healthy patients without the BRCA1 mutation, patients with breast cancer but without the BRCA1 mutation, generally healthy patients with the BRCA1 mutation, and patients with both breast cancer and the BRCA1 mutation. We demonstrated that saliva from breast cancer patients with the BRCA1 mutation is characterized by enhanced antioxidant capacity and a higher degree of oxidative damage to proteins and lipids. The BRCA1 mutation can cause a predisposition to early salivary gland dysfunction, both in patients with breast cancer and in healthy individuals, leading to a decrease in salivary proteins. Using cluster analysis, we showed that salivary peroxidase, advanced glycation end-products (AGE), total antioxidant status (TAS) and malondialdehyde (MDA) may have particular clinical significance in non-invasive diagnostics of breast cancer.

Diet and Biomarkers of Oxidative Damage in Women Previously Treated for Breast Cancer

2005 ◽  
Vol 51 (2) ◽  
pp. 146-154 ◽  
Author(s):  
Cynthia A. Thomson ◽  
Anna R. Giuliano ◽  
James W. Shaw ◽  
Cheryl L. Rock ◽  
Cheryl K. Ritenbaugh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oxidative Damage ◽  
Previously Treated

Abstract 4617: Association between DNA oxidative damage and radiotherapy-induced skin toxicities in breast cancer patients

2020 ◽  
Author(s):  
Moody M. Mihyu ◽  
Isildinha M. Reis ◽  
Cristiane Takita ◽  
Jean L. Wright ◽  
Eunkyung Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oxidative Damage ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Dna Oxidative Damage

Tamoxifen as an antioxidant and cardioprotectant

1995 ◽  
Vol 61 ◽  
pp. 209-219 ◽  
Author(s):  
Helen Wiseman
Keyword(s):  
Breast Cancer ◽  
Oxidative Damage ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Tamoxifen Treatment ◽  
Cholesterol Levels ◽  
Ldl Particles ◽  
Key Factor ◽  
Cardioprotective Action

Tamoxifen is widely used in the treatment of breast cancer and has been proposed as a prophylactic agent in this disease. Tamoxifen is an effective antioxidant and protects membranes and low-density lipoprotein (LDL) particles against oxidative damage. This antioxidant action is shared by endogenous and synthetic oestrogens. The ability of tamoxifen to protect LDL particles against the oxidative damage implicated in atherosclerosis may be an important factor in the reported cardioprotective action of tamoxifen in women being treated for breast cancer. In addition, tamoxifen has been found to act in a similar manner to oestrogens to lower plasma cholesterol levels. The cardioprotective action of tamoxifen may be a key factor in predicting the likely risk/benefit ratio for prophylactic tamoxifen treatment in otherwise healthy women, who have been calculated to be genetically predisposed to developing breast cancer. In the future, predisposition to breast cancer may be determined by genetic screening.

Sign in / Sign up

Export Citation Format

Share Document